Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.70 |
| ▸ | MGLL | Q99685 | 7/20 | 0.65 |
| ▸ | FAAH | O00519 | 5/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.65 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | XBP1 | P17861 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22237613 | 1.00 | PTGS1 (0.70) | PTGS1PTGS2MGLLFAAHMAPK1 | |
| SCHEMBL24637632 | 1.00 | PTGS1 (0.70) | PTGS1PTGS2MGLLFAAHMAPK1 | |
| SCHEMBL14968624 | 1.00 | PTGS1 (0.70) | PTGS1PTGS2MGLLFAAHMAPK1 | |
| SCHEMBL14524212 | 0.98 | PTGS1 (0.67) | PTGS1PTGS2MGLLFAAHMAPK1 | |
| SCHEMBL10014802 | 0.92 | MGLL (0.60) | PTGS1PTGS2MGLLFAAHMAPK1 | |
| SCHEMBL19201659 | 0.88 | PTGS1 (0.56) | PTGS1PTGS2MGLLFAAHMAPK1 | |
| SCHEMBL18515827 | 0.88 | PTGS1 (0.56) | PTGS1PTGS2MGLLFAAHMAPK1 | |
| SCHEMBL15354307 | 0.84 | PTGS1 (0.55) | PTGS1PTGS2MGLLFAAHMAPK1 | |
| Acetic Acid SCHEMBL27987918 | 0.84 | PTGS1 (0.69) | PTGS1PTGS2MGLLFAAHMAPK1 | |
| SCHEMBL2734915 | 0.84 | MGLL (0.52) | PTGS1PTGS2MGLLFAAHMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151890-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024141575-A1 | ANTIBODY-DRUG CONJUGATES TARGETING UPARAP COMPRISING EXATECAN DERIVATIVES | ADCENDO APS (DK) | 2024-07-04 | — | — | WO | disclosed |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-06-27 | — | — | US | disclosed |
| WO-2024129756-A1 | SITE-SPECIFIC ENGINEERED CYSTEINE ANTIBODY DRUG CONJUGATES | SEAGEN INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024130161-A2 | NOVEL CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | BIONECURE THERAPEUTICS INC (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024110905-A1 | ANTI-CEA ANTIBODY DRUG CONJUGATES AND METHODS OF USE | BEIGENE, LTD. (KY) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024044554-A1 | VHH ANTIBODY CONJUGATES WITH HETEROARYL CHELATORS | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044549-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044552-A1 | VHH ANTIBODY DOTA CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20120034246-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| EP-2353611-A2 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | Seattle Genetics, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20110064753-A1 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-7851437-B2 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20100256055-A1 | CONJUGATES OF NEUROTENSIN OR NEUROTENSIN ANALOGS AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-10-07 | — | — | US | disclosed |
| US-20100062008-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-7659241-B2 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090155289-A1 | FURIN-CLEAVABLE PEPTIDE LINKERS FOR DRUG-LIGAND CONJUGATES | PANACEA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| WO-2008136888-A2 | SECOND GENERATION LOW OXYGEN AFFINITY PEGYLATED HEMOGLOBINS AS OXYGEN-CARRYING PLASMA EXPANDERS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064753-A1 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | CD47, CD2, CD22 | PTGS1 3090/4885PTGS2 3364/4885MGLL 3949/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | PTGS1 605/4885PTGS2 1013/4885MGLL 2283/4885 |
| US-20100062008-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | DAD1, DDOST, STT3A | PTGS1 3909/4885PTGS2 4445/4885MGLL 2132/4885 |
| US-20100256055-A1 | CONJUGATES OF NEUROTENSIN OR NEUROTENSIN ANALOGS AND USES THEREOF | NTSR1, NTSR2, NPY1R | PTGS1 2387/4885PTGS2 2777/4885MGLL 4474/4885 |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | PTGS1 4504/4885PTGS2 4518/4885MGLL 3959/4885 |
| US-20120034246-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | PTGS1 4742/4885PTGS2 4834/4885MGLL 4454/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | PTGS1 3954/4885PTGS2 4297/4885MGLL 4648/4885 |
| US-20090155289-A1 | FURIN-CLEAVABLE PEPTIDE LINKERS FOR DRUG-LIGAND CONJUGATES | FURIN, TGOLN2, LAMP1 | PTGS1 4405/4885PTGS2 4559/4885MGLL 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.